CN104797296B - 克服化学治疗抗性的雷公藤提取物 - Google Patents

克服化学治疗抗性的雷公藤提取物 Download PDF

Info

Publication number
CN104797296B
CN104797296B CN201380043906.5A CN201380043906A CN104797296B CN 104797296 B CN104797296 B CN 104797296B CN 201380043906 A CN201380043906 A CN 201380043906A CN 104797296 B CN104797296 B CN 104797296B
Authority
CN
China
Prior art keywords
cells
lgt
docetaxel
tripterygium wilfordii
resistant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380043906.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104797296A (zh
Inventor
莫塞斯·辛·萨姆·乔
黄英
王竞华
拉纳德希尔·拉武拉
汪志军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Western University of Health Sciences
Original Assignee
Western University of Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Western University of Health Sciences filed Critical Western University of Health Sciences
Publication of CN104797296A publication Critical patent/CN104797296A/zh
Application granted granted Critical
Publication of CN104797296B publication Critical patent/CN104797296B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380043906.5A 2012-08-19 2013-08-19 克服化学治疗抗性的雷公藤提取物 Active CN104797296B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261684792P 2012-08-19 2012-08-19
US61/684,792 2012-08-19
PCT/US2013/055602 WO2014031543A1 (en) 2012-08-19 2013-08-19 Tripterygium wilfordii extracts to overcome chemotherapy resistance

Publications (2)

Publication Number Publication Date
CN104797296A CN104797296A (zh) 2015-07-22
CN104797296B true CN104797296B (zh) 2019-12-17

Family

ID=50150329

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380043906.5A Active CN104797296B (zh) 2012-08-19 2013-08-19 克服化学治疗抗性的雷公藤提取物

Country Status (9)

Country Link
US (1) US10149876B2 (enExample)
EP (1) EP2888011A4 (enExample)
JP (1) JP6367801B2 (enExample)
CN (1) CN104797296B (enExample)
AU (2) AU2013306058A1 (enExample)
CA (1) CA2880575C (enExample)
HK (2) HK1211888A1 (enExample)
IN (1) IN2015DN01496A (enExample)
WO (1) WO2014031543A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6529138B2 (ja) * 2013-09-13 2019-06-12 ウェスタン ユニバーシティ オブ ヘルス サイエンス 化学療法耐性を克服するためのウィルホルリドａの使用
CN111909119B (zh) * 2020-08-25 2023-06-16 上海诗丹德标准技术服务有限公司 雷公藤来源化合物及其应用和制备方法、药物组合物、杀虫剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916564A (en) * 1990-03-14 1999-06-29 The University of Texas System--Board of Regents Tripterygium wilfordii Hook F extracts and components thereof for immunosuppression
CN102443039A (zh) * 2010-10-14 2012-05-09 中国科学院上海药物研究所 N-取代氨基苯基-14β-氨甲基表雷公藤内酯醇衍生物及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1604661A1 (en) 2003-02-27 2005-12-14 Teruo Nishida Remedy for corneal ulcer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916564A (en) * 1990-03-14 1999-06-29 The University of Texas System--Board of Regents Tripterygium wilfordii Hook F extracts and components thereof for immunosuppression
CN102443039A (zh) * 2010-10-14 2012-05-09 中国科学院上海药物研究所 N-取代氨基苯基-14β-氨甲基表雷公藤内酯醇衍生物及其制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Extract of Tripterygium wilfordii sensitizes drug resistant";Ranadheer Ravula et al.;《J Clin Pharmacol》;20110913;第1364页"1124364" *
"Triptolide circumvents drug-resistant effect";CHEN,YW et al.;《Anti-cancer drugs》;20100228;502-513 *

Also Published As

Publication number Publication date
US10149876B2 (en) 2018-12-11
US20150238553A1 (en) 2015-08-27
AU2018200709B2 (en) 2019-10-24
JP2015529664A (ja) 2015-10-08
JP6367801B2 (ja) 2018-08-01
HK1211888A1 (en) 2016-06-03
AU2013306058A1 (en) 2015-02-19
EP2888011A4 (en) 2016-01-27
AU2018200709A1 (en) 2018-02-22
IN2015DN01496A (enExample) 2015-07-03
CN104797296A (zh) 2015-07-22
CA2880575A1 (en) 2014-02-27
WO2014031543A1 (en) 2014-02-27
HK1212270A1 (en) 2016-06-10
CA2880575C (en) 2023-07-11
EP2888011A1 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
Na et al. Anticarcinogenic effects of water extract of sporoderm-broken spores of Ganoderma lucidum on colorectal cancer in vitro and in vivo
Yang et al. Enhanced oral bioavailability and anti‐tumour effect of paclitaxel by 20 (s)‐ginsenoside Rg3 in vivo
US12251411B2 (en) Methods of treating endometrial cancer using hemp extract
Yuan et al. Cucurbitacins extracted from Cucumis melo L.(CuEC) exert a hypotensive effect via regulating vascular tone
Cheikh et al. Lessons learned from the discovery and development of the sesquiterpene lactones in cancer therapy and prevention
Han et al. Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin‐Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR Pathway
Yang et al. Ilexgenin A induces B16-F10 melanoma cell G1/S arrest in vitro and reduces tumor growth in vivo
CN105764570B (zh) 用于克服化学治疗抗性的雷公藤内酯甲
JP2015214579A (ja) 癌細胞アポトーシス
Lü et al. Oriental herbs as a source of novel anti-androgen and prostate cancer chemopreventive agents
CN104797296B (zh) 克服化学治疗抗性的雷公藤提取物
Hidayat et al. Phytochemical analysis and in vitro cytotoxicity test of black soybean (Glycine soja L.) ethanolic extract as a growth inhibitor of the HCT-116 colon carcinoma cell line
Bhutta et al. Phytochemicals as Novel Therapeutics for Triple‐Negative Breast Cancer: A Comprehensive Review of Current Knowledge
Agarwal et al. Standardized fraction of Xylocarpus moluccensis inhibits inflammation by modulating MAPK-NFκB and ROS-HIF1α-PKM2 activation
Li et al. Overcome multidrug resistance in colorectal cancer by natural compounds
EP3230249B1 (en) 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione as a cancer therapeutic
EP1549330B1 (en) Pomolic acid for treating multidrug resistant tumours
WO2025165375A1 (en) Non-psychoactive multi-cannabinoid and polysaccharide and polysaccharopeptide-based therapeutic compositions and methods of their administration
TW201016214A (en) Synergistic pharmaceutical composition for the treatment of cancers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1212270

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1212270

Country of ref document: HK